Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

Completed

Conditions studied: Non-muscle Invasive Bladder Cancer

In brief

The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.

Key facts

Study ID

NCT06126796

Run by

Mayo Clinic

People needed

107

Starts

2023-11-16

Expected to finish

2025-09-08

Last updated by the study team

2026-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence.
• Able to provide urine for testing and comply with study protocol.
• Have an email address and be willing to complete surveys online.

You may not qualify if…

• History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma)
• Patients with predominant (>50%) variant histology
• Patients with a history of upper tract and/or urethral cancer
• Women who are pregnant

Where it is running

• Mayo Clinic in Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.